86 related articles for article (PubMed ID: 22231458)
1. A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT.
Martín-Antonio B; Álvarez-Laderas I; Cardesa R; Márquez-Malaver F; Baez A; Carmona M; Falantes J; Suarez-Lledo M; Fernández-Avilés F; Martínez C; Rovira M; Espigado I; Urbano-Ispizua Á
Bone Marrow Transplant; 2012 Sep; 47(9):1206-11. PubMed ID: 22231458
[TBL] [Abstract][Full Text] [Related]
2. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT.
Martín-Antonio B; Suarez-Lledo M; Arroyes M; Fernández-Avilés F; Martínez C; Rovira M; Espigado I; Gallardo D; Bosch A; Buño I; Martínez-Laperche C; Jiménez-Velasco A; de la Cámara R; Brunet S; Nieto JB; Urbano-Ispizua A
Bone Marrow Transplant; 2013 Sep; 48(9):1205-11. PubMed ID: 23542224
[TBL] [Abstract][Full Text] [Related]
3. Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors.
Bosch-Vizcaya A; Pérez-García A; Brunet S; Solano C; Buño I; Guillem V; Martínez-Laperche C; Sanz G; Barrenetxea C; Martínez C; Tuset E; Lloveras N; Coll R; Guardia R; González Y; Roncero JM; Bustins A; Gardella S; Fernández C; Buch J; Gallardo D;
Biol Blood Marrow Transplant; 2012 Jan; 18(1):100-5. PubMed ID: 21703972
[TBL] [Abstract][Full Text] [Related]
4. NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation.
van der Straaten HM; Paquay MM; Tilanus MG; van Geloven N; Verdonck LF; Huisman C
Biol Blood Marrow Transplant; 2011 Aug; 17(8):1231-6. PubMed ID: 21215810
[TBL] [Abstract][Full Text] [Related]
5. HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry.
Crocchiolo R; Ciceri F; Fleischhauer K; Oneto R; Bruno B; Pollichieni S; Sacchi N; Sormani MP; Fanin R; Bandini G; Bonifazi F; Bosi A; Rambaldi A; Alessandrino PE; Falda M; Bacigalupo A
Bone Marrow Transplant; 2009 Nov; 44(9):571-7. PubMed ID: 19363528
[TBL] [Abstract][Full Text] [Related]
6. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
7. Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
Ferrá C; Sanz J; de la Cámara R; Sanz G; Bermúdez A; Valcárcel D; Rovira M; Serrano D; Caballero D; Espigado I; Morgades M; Heras I; Solano C; Duarte R; Barrenetxea C; García-Noblejas A; Díez-Martin JL; Iriondo A; Carreras E; Sierra J; Sanz MA; Ribera JM;
Biol Blood Marrow Transplant; 2010 Jul; 16(7):957-66. PubMed ID: 20144909
[TBL] [Abstract][Full Text] [Related]
8. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
9. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I
Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome.
Talarn C; Urbano-Ispizua A; Martino R; Pérez-Simón JA; Batlle M; Herrera C; Granell M; Gaya A; Torrebadell M; Fernández-Avilés F; Aymerich M; Marín P; Sierra J; Montserrat E
Haematologica; 2007 Dec; 92(12):1655-63. PubMed ID: 18055989
[TBL] [Abstract][Full Text] [Related]
13. Genetic variations of interleukin-23R (1143A>G) and BPI (A645G), but not of NOD2, are associated with acute graft-versus-host disease after allogeneic transplantation.
Wermke M; Maiwald S; Schmelz R; Thiede C; Schetelig J; Ehninger G; Bornhäuser M; Wassmuth R
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1718-27. PubMed ID: 20541026
[TBL] [Abstract][Full Text] [Related]
14. G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation.
Chang YY; Greinix HT; Dickinson AM; Wolff D; Jackson GH; Andreesen R; Holler E; Hildebrandt GC
Cytokine; 2009 Dec; 48(3):218-25. PubMed ID: 19720544
[TBL] [Abstract][Full Text] [Related]
15. The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation.
Antoun A; Vekaria D; Salama RA; Pratt G; Jobson S; Cook M; Briggs D; Moss P
Br J Haematol; 2012 Dec; 159(5):589-98. PubMed ID: 23025544
[TBL] [Abstract][Full Text] [Related]
16. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched/haploidentical hematopoietic SCT.
Luo XH; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Jan; 43(1):29-36. PubMed ID: 18776927
[TBL] [Abstract][Full Text] [Related]
17. Patients receiving HLA-haploidentical/partially matched related allo-HSCT can achieve desirable health-related QoL that is comparable to that of patients receiving HLA-identical sibling allo-HSCT.
Mo XD; Xu LP; Liu DH; Chen YH; Han W; Zhang XH; Chen H; Wang Y; Wang JZ; Liu KY; Huang XJ
Bone Marrow Transplant; 2012 Sep; 47(9):1201-5. PubMed ID: 22231459
[TBL] [Abstract][Full Text] [Related]
18. [Impact of HLA compatibility on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia].
ZHANG Y; CHEN YK; FAN ZP; XU D; JIANG QL; SUN J; LIU QF
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):438-42. PubMed ID: 21421478
[TBL] [Abstract][Full Text] [Related]
19. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
